Novo Nordisk is committed to doing everything we can to improve the treatment of diseases. This includes providing as much information as we can to healthcare professionals, healthcare organisations and patients about the proper use of the medicines and delivery systems we manufacture.
Collaborations with healthcare professionals and healthcare organisations help us to drive innovation and develop new medicines, enhance quality of health education and identify patient needs.
Novo Nordisk supports transparency and is committed to compliance with disclosing our financial relationships related to our collaborations with the medical community as required by our industry guideline, namely the ABPI Code of Practice. We believe transparency of financial relationships between those with whom we collaborate is very important to maintaining trust-based relationships with our patients and the public.
In line with Gender Pay Gap Reporting (GPGR) regulations, all UK companies with more than 250 employees are required to publish their GPGR statistics using data as of 5th April 2021. The metrics cover the gap in pay, the gap in bonus payments, the proportion of men/women at different pay quartiles, and proportion of men/women receiving bonus pay-outs over the previous 12 months period (6 April 2020 to 5 April 2021).
At Novo Nordisk Limited, we are committed to treating pay equality, and diversity and inclusion, with the highest priority. We have a number of activities focused on ensuring that male and female employees are paid equally for work of the same value, and we do not tolerate discrimination on gender or any other protected grounds.